Cytokinetics Stock Price (NASDAQ:CYTK)

Add to My Stocks
$16.4 $0.6 (3.53%) CYTK stock closing price Apr 28, 2017 (Closing)
YOUR DAILY UPDATE ON
CYTK
Cytokinetics
28 APR 2017
amigobulls logo
CYTK hand_up
CYTK vs S&P 500
Closing Price: Apr 28, 2017
CYTK
$16.4 ( -3.53%)
S&P 500
2384.2 ( -0.19%)
CYTK
52 Week Price Range
1 Year Return: 105.81%
Q4 Growth*
Excellent
Profitable ?
Yes
net image
2016 Q4 Net Profit
14.1%
PE Valuation
Expensive*
home image
Rating
CYTK AVERAGE
☆ ☆ ☆ ☆ ☆★ ★ ★ ★ ★
Double Tap To Exit Full Screen
0:00
/

Cytokinetics Snapshot Video

14 5 2

CYTK Stock Details

Prev Close* : $17.00
Market Cap:
$735.1M
Day Low: $15
52 Week Low: $7.18
Open: $15.95
Volume: 1114449
Day High: $16.6
52 Week High: $17.20
Dividend:
N/A

Latest Stock Market News

Latest Articles

Cytokinetics News - From Partners

Cytokinetics Added to S&P SmallCap 600   by Globe Newswire on Apr 21, 2017
What Took So Long?   by Zacks on Dec 29, 2016

CYTK Stockcharts

View CYTK PE ratio, PS ratio stocks charts and compare with peers.
CYTK Chart
Note: Compare Cytokinetics stock price history with the index and industry peers.

Cytokinetics Valuation

PE ratio
(price earnings ratio)
54.67
PS ratio (
price to sales ratio
)
6.25
PB ratio (
price to book ratio
)
9.43

Cytokinetics Returns

ROE
(return on equity)
21%

Cytokinetics Financial Ratios

Asset Turnover
0.81
Receivables Turnover
7.94
Debt to Equity
0.32

CYTK Industry Peers

Company Price Change (%)
Chelsea Therapeutics (CHTP)6.520.03 (0.46%)
Atara Bio (ATRA)17.10.25 (1.44%)
Amgen (AMGN)163.320.6 (0.37%)
Voyager Therapeutics (VYGR)10.440.16 (1.51%)
Biogen Inc (BIIB)271.215.36 (1.94%)
Acorda Therapeutics (ACOR)16.150.6 (3.86%)
Ionis Pharma (IONS)48.190.63 (1.32%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
MiMedx (MDXG)12.691.29 (11.32%)
Regeneron Pharma (REGN)388.4921.87 (5.97%)
Evogene (EVGN)5.360.3 (5.93%)
Chromadex (CDXC)3.110.15 (5.07%)
Sarepta Therapeutics (SRPT)36.261.54 (4.44%)
Acorda Therapeutics (ACOR)16.150.6 (3.86%)
Alkermes (ALKS)58.251.95 (3.46%)
Top gainers from Medical-Biomed-Genetics industry
* As of Apr 29, 2017
CompanyPriceChange (%)
Sorrento Therapeutics (SRNE)1.950.15 (7.14%)
Revance (RVNC)21.751.55 (6.65%)
Innoviva (INVA)11.7850.81 (6.43%)
ZIOPHARM Oncology (ZIOP)7.040.47 (6.26%)
Alder BioPharma (ALDR)20.051.3 (6.09%)
Mirati Therapeutics (MRTX)4.550.23 (4.82%)
Idera Pharma (IDRA)2.350.1 (4.08%)
Top losers from Medical-Biomed-Genetics industry
* As of Apr 29, 2017

Cytokinetics, Inc. Stock News - Partner Headlines

Cytokinetics Financial Statements

income statement20162015201420132012
Net Sales Or Revenues106.4M28.65M46.94M30.64M7.55M
Net Income16.45M-37.5M-14.64M-33.71M-40.37M
Total Operating Expense87.71M66.05M61.68M64.54M48.01M
view Cytokinetics, Inc. income statement
balance sheet20162015201420132012
Total Assets170.14M115.23M132.96M83.18M77.55M
Total Liabilities75.78M46.64M40.9M28.74M7.46M
Shareholders Equity94.36M68.59M92.06M54.44M70.08M
view Cytokinetics, Inc. balance sheet
cash flow statement20162015201420132012
Net Increase (Decrease) In Assets Liabilities12.12M37.24M-34.01M22.04M2.61M
Net Cash From (Used By) Operating Activities36.98M4.88M-44.84M-7.71M-33.43M
Increase (Decrease) In Prop Plant And Equipment-1.56M-0.56M-1.1M-0.52M-0.12M
view Cytokinetics, Inc. cashflow statement

Cytokinetics Stock Message Board

As of last trading day, Cytokinetics stock price was 16.4. Cytokinetics market capitalization is 735.1M and it represents the total market value of CYTK stock. Cytokinetics valuation can be guaged using various valuation metrics like the price to earnings ratio.

For recognizing and analyzing the real performance of Cytokinetics stock, it is a standard practise to adjust historical stock prices to remove gaps caused by stock splits, dividends and distributions. The volume number in Cytokinetics stock quote data shows the number of shares traded. For Ex: 1114449 Cytokinetics shares were traded as of last trading day, as seen from Cytokinetics stock chart. Cytokinetics stock price history has details about historical stock quotes, P/E ratios and price to sales ratios.